Tagged with M

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz.   Besides the large business platform…

China Steven Lynch, managing director of the British Chamber of Commerce in China, introduces the Chamber’s activities in support of their members, the research they are undertaking to produce a position paper on UK PLC in China in 2019 and the great opportunities for British businesses in China.   Brexit does…

Turkey Mahmut Oguzcan, country business leader of 3M Turkey, offers his expert insights into the Turkish medical devices market. He explains how Turkey’s Health Transformation Program (HTP) and private-public partnership (PPP) models have created opportunities and challenges for 3M and outlines its commitment to Turkey moving forward.   Turkey is home…

Malaysia Chuwn Leong Ch’ng, CEO of Thunder Print, presents his company’s strategic role within the Malaysian healthcare industry to provide a high-quality packaging services for all type of health products, from medicines to health supplements.   Today, we are one of the few printers in Malaysia that offer a complete range…

Spain Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he gives an overview of what differentiates Spain and Labiana in the competitive world of pharmaceutical production.   The old business…

Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…

Malaysia Robert Kruit, chief executive for Zuellig Malaysia and Brunei, discusses Zuellig’s plans to expand beyond distribution and diversify its offering in the healthcare sector, and how Zuellig’s investments into digital health, commercial solutions, and animal health further the goal of making healthcare more accessible.   The pharmaceutical segment [in Malaysia]…

Spain Xavier Carbonell, CEO of Palex Group, a leading Spanish medical device player, discusses how the company’s growth has been triggered by acquisitions to grow their portfolio and distribution arm, as well as how they are positioning themselves as a gateway for foreign companies wishing to bring medical devices to the…

Malaysia Tan Sri Dato’ Ariffin Yusuf, founder and managing director of Primabumi, explains how he came to build Primabumi in 1975 and how he managed to position the company as a strategic partner for healthcare companies interested in winning public tenders. With his long business experience with the government, he also…

Malaysia Halal pharmaceuticals – medicines that do not contain any alcohol, parts of animals such as dogs, pigs, bees, or any other substances prohibited as ‘haram’ under Shariah law – are becoming increasingly widespread globally. This trend is especially prevalent in the Asia Pacific region, where the significant Muslim populations of…

Singapore Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s relocation to Asia, and the upcoming rollout of a global Phase III clinical trial for its innovative new Alzheimer’s drug.   As a small, innovative biotech company, we are looking…

Turkey Sule Mene, co-founder, president and CEO of Mene Health Group, shares with PharmaBoardroom the journey of her company starting as the first government-approved CRO of Turkey, its parallel growth alongside the increasingly prominent clinical trial environment of the country, evolution to becoming a value chain group of companies in clinical…